Please assess the completion status of the following clinical trial:

Trial Title: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Part 1:~Inclusion Criteria:~* Men and women \>18 years~* Eastern Cooperative Oncology Group (ECOG) status = 0 to 1~* Subjects with unresectable Stage III or IV melanoma who are either refractory or intolerant to, or have refused standard therapy for treatment of metastatic melanoma~* Subject must have histologic or cytologic confirmation of advanced melanoma~* Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical risk and must consent to pre- and post-treatment biopsies~Exclusion Criteria:~* Active or progressing brain metastases~* Other concomitant malignancies (with some exceptions per protocol)~* Active or history of autoimmune disease~* Positive test for human immunodeficiency virus (HIV) 1\&2 or known acquired immunodeficiency syndrome (AIDS)~* History of any hepatitis~* Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40,and anti-CD40 antibodies. However, half the patients must have progressed on anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) monoclonal antibody therapy~Part 2, 3 and 4:~Inclusion Criteria~* Men and women \>16 years~* Eastern Cooperative Oncology Group (ECOG) status = 0 to 1~* Subjects with unresectable Stage III or IV melanoma who are either refractory or intolerant to, or have refused standard therapy for treatment of metastatic melanoma~* Subjects must never received anti-CTLA4 therapy~* Subjects must have histologic or cytologic confirmation of advanced melanoma~* Subjects must have at least two measurable lesions at baseline by CT or MRI as per RECIST 1.1 criteria~* Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical risk and must consent to pre- and post-treatment biopsies~* Subjects in Part 4 must have brain metastases~Exclusion Criteria~* Active or progressing brain metastases (except for Part 4 subjects)~* Other concomitant malignancies (with some exceptions per protocol)~* Active or history of autoimmune disease~* Positive test for HIV 1\&2 or known AIDS~* History of any hepatitis~* Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40,and anti-CD40 antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1-Cohort 1 and 2: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
- Part 2-Arm A: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
- Part 3-Arm A: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
- Part 3-Arm B: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously as specified
- Part 4-Arm D: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
- Part 4-Arm E: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).